Back to top
more

Hims & Hers Health (HIMS)

(Delayed Data from NYSE)

$16.88 USD

16.88
9,972,908

+1.05 (6.63%)

Updated May 24, 2024 04:00 PM ET

After-Market: $16.90 +0.02 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Charles River (CRL) Banks on RMS Growth Amid Competition

by Zacks Equity Research

Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.

Zacks Market Edge Highlights: Wingstop, Super Micro Computer, Medpace, Him & Hers Health and Vita Coco

by Zacks Equity Research

Wingstop, Super Micro Computer, Medpace, Him & Hers Health and Vita Coco are part of the Zacks Market Edge blog.

Medtronic's (MDT) OmniaSecure Lead Favored in the LEADR Trial

by Zacks Equity Research

Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.

Reasons to Include Alcon (ALC) in Your Portfolio Right Now

by Zacks Equity Research

New product launches and strong solvency bode well for Alcon (ALC).

Tracey Ryniec headshot

5 Top Ranked Strong Buy Growth Stocks for 2024

by Tracey Ryniec

Get double digit earnings growth this year.

Boston Scientific (BSX) Rides on Emerging Markets, MedSurg

by Zacks Equity Research

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care

by Zacks Equity Research

Veracyte's (VCYT) new studies leverage Afirma GRID's whole-transcriptome approach to uncover novel molecular signatures and alterations.

Globus Medical (GMED) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Globus Medical (GMED) outperforms the industry due to its stellar quarterly performance and impactful launches.

Bruker (BRKR) Gains Market Share on Innovation Amid Macro Woes

by Zacks Equity Research

Bruker's (BRKR) BSI Nano business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.

Here's Why You Should Buy Haemonetics (HAE) Stock Now

by Zacks Equity Research

Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).

Medtronic's (MDT) MiniMed 780G AID System Wins New Accolade

by Zacks Equity Research

Medtronic's (MDT) MiniMed 780G system gets recognized among Fast Company's 2024 World Changing Ideas.

Evolus (EOLS) Releases Favorable Dermal Fillers Study Data

by Zacks Equity Research

The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.

Here's Why You Should Hold on to Abbott (ABT) Stock for Now

by Zacks Equity Research

Abbott's (ABT) share recovery in the Nutrition business buoys optimism.

IDEXX (IDXX) Witnesses Rising Expenses, Currency Issues

by Zacks Equity Research

IDEXX (IDXX) is being hurt by geopolitical instability, including the current war in Ukraine, which has affected supply chain operations globally.

Here's Why Investors Should Buy ResMed (RMD) Stock Now

by Zacks Equity Research

Investors are optimistic about ResMed's (RMD) potential in digital health and expansion in the international market.

Medtronic (MDT) Reports Favorable SPHERE Per-AF Trial Outcome

by Zacks Equity Research

Medtronic's (MDT) Affera Mapping and Ablation System with Sphere-9 Catheter achieves endpoints for safety and efficacy for the treatment of AFib.

Is Hims & Hers Health (HIMS) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Hims & Hers Health (HIMS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Thermo Fisher (TMO) Unveils New Extended Blood Genotyping Array

by Zacks Equity Research

Thermo Fisher's (TMO) new Applied Biosystems Axiom BloodGenomiX Array and Software provide a high-throughput solution for more precise blood matching research.

Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now

by Zacks Equity Research

QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.

Earnings Estimates Rising for Hims & Hers Health (HIMS): Will It Gain?

by Zacks Equity Research

Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Henry Schein (HSIC) Extends Partnership With Special Olympics

by Zacks Equity Research

Henry Schein's (HSIC) extended collaboration with Special Olympics is likely to promote wellness and health education for athletes with ID around the world.

Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know

by Zacks Equity Research

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Here's Why You Should Retain Zimmer Biomet (ZBH) Stock for Now

by Zacks Equity Research

Strong procedure recovery and progress on the four-pillar strategy bode well for Zimmer Biomet (ZBH).

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FYC

Boston Scientific (BSX) Gains From MedSurg Growth & Buyouts

by Zacks Equity Research

Within Neuromodulation, Boston Scientific's pain business is consistently gaining traction, banking on strength in the spinal cord stimulation (SCS) business.